As part of the EU, France has experienced severe shortages in supplies of the AstraZeneca jab, which came amid a heated debate on its overall efficacy. Now that new studies have emerged alleging it could be more effective than Pfizer’s brainchild, the EU is expected to press AstraZeneca to ultimately meet all of its initial delivery targets.